38 research outputs found
In Vitro Metabolism of Haloperidol and Sila-Haloperidol: New Metabolic Pathways Resulting from Carbon/Silicon Exchange □ S
ABSTRACT: The neurotoxic side effects observed for the neuroleptic agent haloperidol have been associated with its pyridinium metabolite. In a previous study, a silicon analog of haloperidol (sila-haloperidol) was synthesized, which contains a silicon atom instead of the carbon atom in the 4-position of the piperidine ring. In the present study, the phase I metabolism of sila-haloperidol and haloperidol was studied in rat and human liver microsomes. The phase II metabolism was studied in rat, dog, and human hepatocytes and also in liver microsomes supplemented with UDP-glucuronic acid (UDPGA). A major metabolite of haloperidol, the pyridinium metabolite, was not formed in the microsomal incubations with silahaloperidol. For sila-haloperidol, three metabolites originating from opening of the piperidine ring were observed, a mechanism that has not been observed for haloperidol. One of the significant phase II metabolites of haloperidol was the glucuronide of the hydroxy group bound to the piperidine ring. For sila-haloperidol, the analogous metabolite was not observed in the hepatocytes or in the liver microsomal incubations containing UDPGA. If silanol (SiOH) groups are not glucuronidated, introducing silanol groups in drug molecules could provide an opportunity to enhance the hydrophilicity without allowing for direct phase II metabolism. To provide further support for the observed differences in metabolic pathways between haloperidol and sila-haloperidol, the metabolism of another pair of C/Si analogs was studied, namely, trifluperidol and sila-trifluperidol. These studies showed the same differences in metabolic pathways as between sila-haloperidol and haloperidol. Haloperidol was developed in the late 1950s and was found to be a potent neuroleptic agent In the search for analogs of haloperidol, a silicon analog (silahaloperidol) was synthesized, where the quaternary R 3 COH carbon atom in the piperidine ring was replaced by a silicon atom (R 3 SiOH). The synthesis and the physicochemical and pharmacological properties of sila-haloperidol have been reported previously The use of organosilicon chemistry in drug design has been reviewed previousl
Electrochemistry on-line with mass spectrometry : instrumental methods for in vitro generation and detection of drug metabolites
The main goal of these studies was the development of new techniques on-line with electrospray mass spectrometry for in vitro generation and characterization of drug metabolites. In order to achieve this goal two electrochemical techniques have been developed for oxidation of drugs and xenobiotics on-line with electrospray mass spectrometry. ...
Zie: Summary
Use of Electrochemical Oxidation and Model Peptides To Study Nucleophilic Biological Targets of Reactive Metabolites: The Case of Rimonabant
Electrochemical
oxidation of drug molecules is a useful tool to
generate several different types of metabolites. In the present study
we developed a model system involving electrochemical oxidation followed
by characterization of the oxidation products and their propensity
to modify peptides. The CB1 antagonist rimonabant was chosen as the
model drug. Rimonabant has previously been shown to give high covalent
binding to proteins in human liver microsomes and hepatocytes and
the iminium ion and/or the corresponding aminoaldehyde formed via
P450 mediated α-carbon oxidation of rimonabant was proposed
to be a likely contributor. This proposal was based on the observation
that levels of covalent binding were significantly reduced when iminium
species were trapped as cyanide adducts but also following addition
of methoxylamine expected to trap aldehydes. Incubation of electrochemically
oxidized rimonabant with peptides resulted in peptide adducts to the
N-terminal amine with a mass increment of 64 Da. The adducts were
shown to contain an addition of C<sub>5</sub>H<sub>4</sub> originating
from the aminopiperidine moiety of rimonabant. Formation of the peptide
adducts required further oxidation of the iminium ion to short-lived
intermediates, such as dihydropyridinium species. In addition, the
metabolites and peptide adducts generated in human liver microsomes
were compared with those generated by electrochemistry. Interestingly,
the same peptide modification was found when rimonabant was coincubated
with one of the model peptides in microsomes. This clearly indicated
that reactive metabolite(s) of rimonabant identical to electrochemically
generated species are also present in the microsomal incubations.
In summary, electrochemical oxidation combined with peptide trapping
of reactive metabolites identified a previously unobserved bioactivation
pathway of rimonabant that was not captured by traditional trapping
agents and that may contribute to the <i>in vitro</i> covalent
binding
Oxygen surrogate systems for supporting human drug-metabolizing cytochrome P450 enzymes
Oxygen surrogates (OSs) have been used to support cytochrome P450 (P450) enzymes for diverse purposes in drug metabolism research, including reaction phenotyping, mechanistic and inhibition studies, studies of redox partner interactions, and to avoid the need for NADPH or a redox partner. They also have been used in engineering P450s for more cost-effective, NADPH-independent biocatalysis. However, despite their broad application, little is known of the preference of individual P450s for different OSs or the substrate dependence of OS-supported activity. Furthermore, the biocatalytic potential of OSs other than cumene hydroperoxide (CuOOH) and hydrogen peroxide (H2O2) is yet to be explored. Here, we investigated the ability of the major human drug-metabolizing P450s, namely CYP3A4, CYP2C9, CYP2C19, CYP2D6, and CYP1A2, to use the following OSs: H2O2, tert-butyl hydroperoxide (tert-BuOOH), CuOOH, (diacetoxyiodo)benzene, and bis(trifluoroacetoxy)iodobenzene. Overall, CuOOH and tert-BuOOH were found to be the most effective at supporting these P450s. However, the ability of P450s to be supported by OSs effectively was also found to be highly dependent on the substrate used. This suggests that the choice of OS should be tailored to both the P450 and the substrate under investigation, underscoring the need to employ screening methods that reflect the activity toward the substrate of interest to the end application. SIGNIFICANCE STATEMENT: Cytochrome P450 (P450) enzymes can be supported by different oxygen surrogates (OSs), avoiding the need for a redox partner and costly NADPH. However, few data exist comparing relative activity with different OSs and substrates. This study shows that the choice of OS used to support the major drug-metabolizing P450s influences their relative activity and regioselectivity in a substrate-specific fashion and provides a model for the more efficient use of P450s for metabolite biosynthesis